Nuvation Bio Inc. (NUVB) Debt / Equity
- 2026-06-30: Debt/Equity Ratio 0.98.
- 2026-03-31: Debt/Equity Ratio 0.17.
- 2025-12-31: Debt/Equity Ratio 0.17.
- 2025-09-30: Debt/Equity Ratio 0.16.
Complete source-backed debt/equity ratio history.
- Available history
- 2025-06-30 to 2026-06-30
- Data captured
Historical Debt/Equity Ratio
| Date | Debt/Equity Ratio |
|---|---|
| 2026-06-30 | 0.98 |
| 2026-03-31 | 0.17 |
| 2025-12-31 | 0.17 |
| 2025-09-30 | 0.16 |
| 2025-06-30 | 0.14 |
Annual Debt/Equity Ratio
| Date | Debt/Equity Ratio |
|---|---|
| 2025-12-31 | 0.17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |